A Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Dose and Multiple Doses of GSK3389404 in Chronic Hepatitis B Subjects

Trial Profile

A Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Dose and Multiple Doses of GSK3389404 in Chronic Hepatitis B Subjects

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Sep 2017

At a glance

  • Drugs IONIS-HBV-LRx (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 06 Sep 2017 Planned number of patients changed from 120 to 150.
    • 06 Sep 2017 Planned End Date changed from 12 Feb 2018 to 28 Jan 2019.
    • 06 Sep 2017 Planned primary completion date changed from 12 Feb 2018 to 4 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top